Ignite Creation Date:
2024-05-06 @ 8:06 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06255847
Status:
RECRUITING
Last Update Posted:
2024-02-13
First Post:
2024-01-15
Brief Title:
Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM
Sponsor:
Shanxi Bethune Hospital
Organization:
Shanxi Bethune Hospital
Study Overview
Official Title:
A Multicenter Open-label Clinical Study of a Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone Regimen for the Treatment of Patients With Debilitating Relapsed-refractory Multiple Myeloma
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label clinical study to evaluate the efficacy and safety of a multicenter open-label clinical study of a base-reduced-dose pomalidomide cyclophosphamide combined with dexamethasone PCd regimen for the treatment of patients with debilitating relapsed refractory multiple myeloma
Subjects meeting the enrollment criteria were screened for entry into the study and treated with the appropriate regimen all patients enrolled in the study did not receive medications other than those specified in the regimen for the treatment of myeloma during the study period except for supportive care The primary endpoint of the study is ORR secondary study endpoints include efficacy above VGPR progression-free survival PFS overall survival OS TTNT safety and life scale assessment
Subjects meeting the enrollment criteria were screened for entry into the study and treated with the appropriate regimen all patients enrolled in the study did not receive medications other than those specified in the regimen for the treatment of myeloma during the study period except for supportive care The primary endpoint of the study is ORR secondary study endpoints include efficacy above VGPR progression-free survival PFS overall survival OS TTNT safety and life scale assessment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None